Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Prostate and Urologic Cancers Research Group / Completed validation of PCA3 as a urine-based test for early detection and diagnosis of prostate cancer - FDA approved

Completed validation of PCA3 as a urine-based test for early detection and diagnosis of prostate cancer - FDA approved

Click here to view PCA3 information in more detail.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 10/27/2016

Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.

Announcement